Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus

被引：13

作者：

Park, Sangmi S. ^{[1
]}

Ortega, Romy Rodriguez ^{[1
]}

Agudelo, Christina W. ^{[1
]}

Perez, Jessica Perez ^{[1
]}

Gandara, Brais Perez ^{[1
]}

Garcia-Arcos, Itsaso ^{[1
]}

McCarthy, Cormac ^{[2
]}

Geraghty, Patrick ^{[1
]}

机构：

[1] State Univ New York Downstate Hlth Sci Univ, Dept Med, Brooklyn, NY 11203 USA

[2] Univ Coll Dublin, Educ & Res Ctr, Sch Med, St Vincents Univ Hosp, Dublin D04 T6F4, Ireland

来源：

MEDICINA-LITHUANIA | 2021年 / 57卷 / 04期

关键词：

alpha-1; antitrypsin; diabetes mellitus; inflammation; apoptosis; PHOSPHOLIPID TRANSFER PROTEIN; ALPHA(1)-ANTITRYPSIN THERAPY; NEUTROPHIL ELASTASE; DOUBLE-BLIND; CATHEPSIN-G; DEFICIENCY; INHIBITOR; GENE; DENSITY; PLASMA;

D O I：

10.3390/medicina57040397

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Alpha-1 antitrypsin (AAT) has established anti-inflammatory and immunomodulatory effects in chronic obstructive pulmonary disease but there is increasing evidence of its role in other inflammatory and immune-mediated conditions, like diabetes mellitus (DM). AAT activity is altered in both developing and established type 1 diabetes mellitus (T1DM) as well in established type 2 DM (T2DM). Augmentation therapy with AAT appears to favorably impact T1DM development in mice models and to affect beta-cell function and inflammation in humans with T1DM. The role of AAT in T2DM is less clear, but AAT activity appears to be reduced in T2DM. This article reviews these associations and emerging therapeutic strategies using AAT to treat DM.

引用

页数：9

共 50 条

[31] Alpha-1 Antitrypsin: A Potent Anti-Inflammatory and Potential Novel Therapeutic Agent
Bergin, David A.
Hurley, Killian
McElvaney, Noel G.
Reeves, Emer P.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2012, 60 (02) : 81 - 97
[32] Alpha-1 Antitrypsin: A Potent Anti-Inflammatory and Potential Novel Therapeutic Agent
David A. Bergin
Killian Hurley
Noel G. McElvaney
Emer P. Reeves
Archivum Immunologiae et Therapiae Experimentalis, 2012, 60 : 81 - 97
[33] Identification Of Novel Binding Partners To Fully Understand The Therapeutic Potential Of Alpha-1 Antitrypsin
O'Brien, M. E.
Bergin, D. A.
McCarthy, C.
Reeves, E. P.
McElvaney, N. G.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
[34] Systemic vasculitis and alpha-1 antitrypsin deficiency type PiZZ: a case report
Sadoun, D
Fartoukh, M
Jaillet, H
Valeyre, D
Battesti, JP
Guillevin, L
ANNALES DE MEDECINE INTERNE, 1997, 148 (08): : 579 - 581
[35] Alpha1-Antitrypsin (AAT) - a novel therapy for type 1 diabetes?
不详
DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 479 - 479
[36] ALPHA-1 ANTITRYPSIN AND NEOPLASMS
ROVIRA, EC
LOPEZ, JVA
CLOSA, AS
MEDICINA CLINICA, 1984, 82 (12): : 561 - 561
[37] Alpha 1 Antitrypsin (AAT) Gene Therapy for the Prevention of Type 1 Diabetes
Song, Sihong
Lu, Yuanqing
Tang, Mei
Zhang, Bin
Wasserfall, Clive
Campbell-Thompson, Martha
Atkinson, Mark
MOLECULAR THERAPY, 2006, 13 : S30 - S30
[38] Alpha-1 antitrypsin deficiency
Jolobe, O. M. P.
AMERICAN JOURNAL OF MEDICINE, 2008, 121 (07): : E13 - E13
[39] ALPHA-1 ANTITRYPSIN DEFICIENCY
HARRIS, DJ
JOURNAL OF MEDICAL GENETICS, 1988, 25 (02) : 135 - 136
[40] Alpha-1 Antitrypsin Level Increase During An Inflammatory State: A Potential Cause Of Missed Diagnosis In Alpha-1 Antitrypsin Deficiency
DeLapp, D. A.
Nystrom, P.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193

← 1 2 3 4 5 →